Drugs against SARS-CoV-2: What do we know about their mode of action?

Coralie Valle, Baptiste Martin, Franck Touret, Ashleigh Shannon, Bruno Canard, Jean-Claude Guillemot, Bruno Coutard, Etienne Decroly, Coralie Valle, Baptiste Martin, Franck Touret, Ashleigh Shannon, Bruno Canard, Jean-Claude Guillemot, Bruno Coutard, Etienne Decroly

Abstract

The health emergency caused by the recent Covid-19 pandemic highlights the need to identify effective treatments against the virus causing this disease (SARS-CoV-2). The first clinical trials have been testing repurposed drugs that show promising anti-SARS-CoV-2 effects in cultured cells. Although more than 2400 clinical trials are already under way, the actual number of tested compounds is still limited to approximately 20, alone or in combination. In addition, knowledge on their mode of action (MoA) is currently insufficient. Their first results reveal some inconsistencies and contradictory results and suggest that cohort size and quality of the control arm are two key issues for obtaining rigorous and conclusive results. Moreover, the observed discrepancies might also result from differences in the clinical inclusion criteria, including the possibility of early treatment that may be essential for therapy efficacy in patients with Covid-19. Importantly, efforts should also be made to test new compounds with a documented MoA against SARS-CoV-2 in clinical trials. Successful treatment will probably be based on multitherapies with antiviral compounds that target different steps of the virus life cycle. Moreover, a multidisciplinary approach that combines artificial intelligence, compound docking, and robust in vitro and in vivo assays will accelerate the development of new antiviral molecules. Finally, large retrospective studies on hospitalized patients are needed to evaluate the different treatments with robust statistical tools and to identify the best treatment for each Covid-19 stage. This review describes different candidate antiviral strategies for Covid-19, by focusing on their mechanism of action.

Conflict of interest statement

The authors have no competing interest.

© 2020 John Wiley & Sons, Ltd.

Figures

FIGURE 1
FIGURE 1
SARS‐CoV‐2 life cycle and potential mechanisms of action of currently evaluated therapeutics. SARS‐CoV‐2 life cycle and the presumed mechanisms of action (MoA) of the main SARS‐CoV‐2 replication inhibitors. Different compounds are assessed to find compounds targeting the different steps of SARS‐CoV‐2 life cycle. Molecules currently in clinical trials are indicated by a gray star. Therapeutic strategies based on antiviral compounds are indicated in red, and approved drugs used for other diseases or selected by virtual screening are indicated in yellow. The black question marks indicate unknown or elusive MoA in the context of CoV infection. *Corresponding to antibody (Ab) strategies including monoclonal antibodies and plasma from convalescent patient. The Biorender website was used to generate this figure

References

    1. Ksiazek TG, Erdman D, Goldsmith CS, et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med. 2003;348(20):1953‐1966.
    1. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus ADME, RAM F. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012;367(19):1814‐1820.
    1. Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579(7798):265‐269.
    1. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID‐19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054‐1062.
    1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497‐506.
    1. de Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016;14(8):523‐534.
    1. Li F. Receptor recognition mechanisms of coronaviruses: a decade of structural studies. J Virol. 2015;89(4):1954‐1964.
    1. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade‐long structural studies of SARS coronavirus. J Virol. 2020;94(7):120–127.
    1. Coutard B, Valle C, de Lamballerie X, Canard B, Seidah NG, Decroly E. The spike glycoprotein of the new coronavirus 2019‐nCoV contains a furin‐like cleavage site absent in CoV of the same clade. Antiviral Res. 2020;176:104742.
    1. Matsuyama S, Nagata N, Shirato K, Kawase M, Takeda M, Taguchi F. Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2. J Virol. 2010;84(24):12658‐12664.
    1. Markus H, Kleine‐Weber H, Pöhlmann S. A multibasic cleavage site in the spike protein of SARS‐CoV‐2 is essential for infection of human lung cells. Mol Cell. 2020;78(4):779–784.
    1. Belouzard S, Chu VC, Whittaker GR. Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites. Proc Natl Acad Sci U S A. 2009;106(14):5871‐5876.
    1. Millet JK, Whittaker GR. Host cell proteases: critical determinants of coronavirus tropism and pathogenesis. Virus Res. 2015;202:120‐134.
    1. Bestle D, Heindl MR, Limburg H, et al. TMPRSS2 and furin are both essential for proteolytic activation and spread of SARS‐CoV‐2 in human airway epithelial cells and provide promising drug targets. bioRxiv;2020.04.15.042085. . [Accessed May 1, 2020].
    1. Thorlund K, Dron L, Park J, Hsu G, Forrest JI, Mills EJ. A real‐time dashboard of clinical trials for COVID‐19. Lancet Digit Heal. 2020;2:286–287.
    1. Clinical Management of Severe Acute Respiratory Infection When COVID‐19 Is Suspected. . Accessed May 27, 2020.
    1. Zhou G, Zhao Q. Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS‐CoV‐2. Int J Biol Sci. 2020;16(10):1718‐1723.
    1. Cheng Y, Wong R, Soo YOY, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005;24(1):44‐46.
    1. Mair‐Jenkins J, Saavedra‐Campos M, Baillie JK, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta‐analysis. J Infect Dis. 2015;211(1):80‐90.
    1. Yeh K‐M, Chiueh T‐S, Siu LK, et al. Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital. J Antimicrob Chemother. 2005;56(5):919‐922.
    1. Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID‐19. Lancet Infect Dis. 2020;20(4):398‐400.
    1. Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically ill patients with COVID‐19 with convalescent plasma. JAMA. 2020;323:1582–1589.
    1. Li L, Zhang W, Hu Y, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life‐threatening COVID‐19. JAMA. 2020.
    1. Berry JD. Rational monoclonal antibody development to emerging pathogens, biothreat agents and agents of foreign animal disease: the antigen scale. Vet J. 2005;170(2):193‐211.
    1. Hoenen T, Groseth A, Feldmann H. Therapeutic strategies to target the Ebola virus life cycle. Nat Rev Microbiol. 2019;17(10):593‐606.
    1. Wang L, Shi W, Chappell JD, et al. Importance of neutralizing monoclonal antibodies targeting multiple antigenic sites on the Middle East respiratory syndrome coronavirus spike glycoprotein to avoid neutralization escape. J Virol. 2018;92(10):2002–2017.
    1. Hofmann H, Hattermann K, Marzi A, et al. S protein of severe acute respiratory syndrome‐associated coronavirus mediates entry into hepatoma cell lines and is targeted by neutralizing antibodies in infected patients. J Virol. 2004;78(12):6134‐6142.
    1. He Y, Lu H, Siddiqui P, Zhou Y, Jiang S. Receptor‐binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation‐dependent epitopes that induce highly potent neutralizing antibodies. J Immunol. 2005;174(8):4908‐4915.
    1. Sui J, Li W, Murakami A, et al. Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proc Natl Acad Sci U S A. 2004;101(8):2536‐2541.
    1. Greenough TC, Babcock GJ, Roberts A, et al. Development and characterization of a severe acute respiratory syndrome–associated coronavirus–neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice. J Infect Dis. 2005;191(4):507‐514.
    1. Wrapp D, De Vlieger D, Corbett KS, et al. Structural basis for potent neutralization of betacoronaviruses by single‐domain camelid antibodies. Cell. 2020;181(5):1004–1015.
    1. Zhu Z, Chakraborti S, He Y, et al. Potent cross‐reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. Proc Natl Acad Sci U S A. 2007;104(29):12123‐12128.
    1. Walls AC, Park Y‐J, Tortorici MA, Wall A, AT MG, Veesler D. Structure, function, and antigenicity of the SARS‐CoV‐2 spike glycoprotein. Cell. 2020;181:281–292.
    1. Monteil V, Kwon H, Prado P, et al. Inhibition of SARS‐CoV‐2 infections in engineered human tissues using clinical‐grade soluble human ACE2. Cell. 2020;181:905–913.
    1. Imai Y, Kuba K, Penninger JM. The discovery of angiotensin‐converting enzyme 2 and its role in acute lung injury in mice. Exp Physiol. 2008;93:543‐548.
    1. Wang K, Chen W, Zhou YS, et al. SARS‐CoV‐2 invades host cells via a novel route: CD147‐spike protein. bioRxiv. 2020. . Accessed April 5, 2020.
    1. Bian H, Zheng Z‐H, Wei D, et al. Meplazumab treats COVID‐19 pneumonia: an open‐labelled, concurrent controlled add‐on clinical trial. medRxiv. 2020. . Accessed April 4, 2020.
    1. Boriskin YS, Leneva IA, Pécheur E‐I, Polyak SJ. Arbidol: a broad‐spectrum antiviral compound that blocks viral fusion. Curr Med Chem. 2008;15(10):997‐1005.
    1. Touret F, Gilles M, Barral K, et al. in vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS‐CoV‐2 replication. bioRxiv. 2020.
    1. Khamitov RA, Loginova SI, Shchukina VN, Borisevich SV, Maksimov VA, Shuster AM. Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures. Vopr Virusol. 2008;53(4):9‐13.
    1. Deng L, Li C, Zeng Q, et al. Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: a retrospective cohort study. J Infect. 2020;81:1–5.
    1. Chen C, Huang J, Cheng Z, et al. Favipiravir versus arbidol for COVID‐19: a randomized clinical trial. medRxiv. 2020. . Accessed April 4, 2020.
    1. Falzarano D, de Wit E, Martellaro C, Callison J, Munster VJ, Feldmann H. Inhibition of novel β coronavirus replication by a combination of interferon‐α2b and ribavirin. Sci Rep. 2013;3(1):1686.
    1. Barnard DL, Day CW, Bailey K, et al. Enhancement of the infectivity of SARS‐CoV in BALB/c mice by IMP dehydrogenase inhibitors, including ribavirin. Antiviral Res. 2006;71(1):53‐63.
    1. Warren TK, Jordan R, Lo MK, et al. Therapeutic efficacy of the small molecule GS‐5734 against Ebola virus in rhesus monkeys. Nature. 2016;531(7594):381‐385.
    1. Agostini ML, Andres EL, Sims AC, et al. Coronavirus susceptibility to the antiviral remdesivir (GS‐5734) is mediated by the viral polymerase and the proofreading exoribonuclease. MBio. 2018;9(2):e00221–18.
    1. de Wit E, Feldmann F, Cronin J, et al. Prophylactic and therapeutic remdesivir (GS‐5734) treatment in the rhesus macaque model of MERS‐CoV infection. Proc Natl Acad Sci U S A. 2020;117(12):6771‐6776.
    1. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019‐nCoV) in vitro. Cell Res. 2020;30(3):269‐271.
    1. Launch of a European Clinical Trial Against COVID‐19 | Newsroom | INSERM. . Accessed April 6, 2020.
    1. Grein J, Ohmagari N, Shin D, et al. Compassionate use of remdesivir for patients with severe Covid‐19. N Engl J Med. 2020;382:2327–2336.
    1. Cai Q, Yang M, Liu D, et al. Experimental treatment with favipiravir for COVID‐19: an open‐label control study. Engineering, in press. 2020.
    1. Sheahan TP, Sims AC, Zhou S, et al. An orally bioavailable broad‐spectrum antiviral inhibits SARS‐CoV‐2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med. 2020;12:eabb5883.
    1. Agostini ML, Pruijssers AJ, Chappell JD, et al. Small‐molecule antiviral β‐D‐ N 4 ‐hydroxycytidine inhibits a proofreading‐intact coronavirus with a high genetic barrier to resistance. J Virol. 2019;93(24):e01348–19.
    1. Gordon CJ, Tchesnokov EP, Woolner E, et al. Remdesivir is a direct‐acting antiviral that inhibits RNA‐dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J Biol Chem. 2020;295:6785–6797.
    1. Zhang L, Lin D, Sun X, et al. Crystal structure of SARS‐CoV‐2 main protease provides a basis for design of improved α‐ketoamide inhibitors. Science. 2020;368:409–412.
    1. Chu CM, Cheng VCC, Hung IFN, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004;59(3):252‐256.
    1. Bhatnagar T, Murhekar MV, Soneja M, et al. Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: protocol for restricted public health emergency use. Indian J Med Res. 2020;151:184–189.
    1. Cao B, Wang Y, Wen D, et al. A trial of lopinavir‐ritonavir in adults hospitalized with severe Covid‐19. N Engl J Med. 2020;382:1787–1799.
    1. Lim J, Jeon S, Shin HY, et al. Case of the index patient who caused tertiary transmission of COVID‐19 infection in Korea: the application of lopinavir/ritonavir for the treatment of COVID‐19 infected pneumonia monitored by quantitative RT‐PCR. J Korean Med Sci. 2020;35(6):e79.
    1. de Wilde AH, Jochmans D, Posthuma CC, et al. Screening of an FDA‐approved compound library identifies four small‐molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother. 2014;58(8):4875‐4884.
    1. Yamamoto N, Yang R, Yoshinaka Y, et al. HIV protease inhibitor nelfinavir inhibits replication of SARS‐associated coronavirus. Biochem Biophys Res Commun. 2004;318(3):719‐725.
    1. Kadam RU, Wilson IA. Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol. Proc Natl Acad Sci U S A. 2017;114(2):206‐214.
    1. Vigant F, Santos NC, Lee B. Broad‐spectrum antivirals against viral fusion. Nat Rev Microbiol. 2015;13(7):426‐437.
    1. Riva L, Yuan S, Yin X, et al. A large‐scale drug repositioning survey for SARS‐CoV‐2 antivirals. bioRxiv. 2020. . Accessed April 27, 2020.
    1. Crotty S, Maag D, Arnold JJ, et al. The broad‐spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat Med. 2000;6(12):1375‐1379.
    1. Pruijssers AJ, Denison MR. Nucleoside analogues for the treatment of coronavirus infections. Curr Opin Virol. 2019;35:57‐62.
    1. Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature. 2005;436(7053):967‐972.
    1. Ferron F, Subissi L, Silveira De Morais AT, et al. Structural and molecular basis of mismatch correction and ribavirin excision from coronavirus RNA. Proc Natl Acad Sci U S A. 2018;115(2):E162‐E171.
    1. Smith EC, Blanc H, Surdel MC, Vignuzzi M, Denison MR. Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeutics. PLoS Pathog. 2013;9(8):e1003565.
    1. Ströher U, DiCaro A, Li Y, et al. Severe acute respiratory syndrome–related coronavirus is inhibited by interferon‐α. J Infect Dis. 2004;189(7):1164‐1167.
    1. Sheahan TP, Sims AC, Graham RL, et al. Broad‐spectrum antiviral GS‐5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017;9(396):eaal3653.
    1. Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS‐CoV. Nat Commun. 2020;11(1):222.
    1. Furuta Y, Takahashi K, Fukuda Y, et al. In vitro and in vivo activities of anti‐influenza virus compound T‐705. Antimicrob Agents Chemother. 2002;46(4):977‐981.
    1. Kim J‐A, Seong R‐K, Kumar M, Shin OS. Favipiravir and ribavirin inhibit replication of Asian and African strains of Zika virus in different cell models. Viruses. 2018;10(2):72.
    1. Zmurko J, Marques RE, Schols D, Verbeken E, SJF K, Neyts J. The viral polymerase inhibitor 7‐deaza‐2’‐C‐methyladenosine is a potent inhibitor of in vitro Zika virus replication and delays disease progression in a robust mouse infection model. PLoS Negl Trop Dis. 2016;10(5):e0004695.
    1. Delang L, Segura Guerrero N, Tas A, et al. Mutations in the chikungunya virus non‐structural proteins cause resistance to favipiravir (T‐705), a broad‐spectrum antiviral. J Antimicrob Chemother. 2014;69(10):2770‐2784.
    1. Rocha‐Pereira J, Jochmans D, Dallmeier K, Leyssen P, Nascimento MSJ, Neyts J. Favipiravir (T‐705) inhibits in vitro norovirus replication. Biochem Biophys Res Commun. 2012;424(4):777‐780.
    1. Guedj J, Piorkowski G, Jacquot F, et al. Antiviral efficacy of favipiravir against Ebola virus: a translational study in cynomolgus macaques. PLoS Med. 2018;15(3):e1002535.
    1. Oestereich L, Lüdtke A, Wurr S, Rieger T, Muñoz‐Fontela C, Günther S. Successful treatment of advanced Ebola virus infection with T‐705 (favipiravir) in a small animal model. Antiviral Res. 2014;105:17‐21.
    1. Smither SJ, Eastaugh LS, Steward JA, Nelson M, Lenk RP, Lever MS. Post‐exposure efficacy of oral T‐705 (favipiravir) against inhalational Ebola virus infection in a mouse model. Antiviral Res. 2014;104:153‐155.
    1. Shannon A, Selisko B, Le TTN , et al. Favipiravir strikes the SARS‐CoV‐2 at its Achilles heel, the RNA polymerase. Nature Com, in press. 2020.
    1. Jeon S, Ko M, Lee J, et al. Identification of antiviral drug candidates against SARS‐CoV‐2 from FDA‐approved drugs. bioRxiv. 2020. . Accessed April 27, 2020.
    1. Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H, Doerr HW. Treatment of SARS with human interferons. Lancet. 2003;362(9380):293‐294.
    1. Hensley LE, Fritz EA, Jahrling PB, Karp C, Huggins JW, Geisbert TW. Interferon‐β 1a and SARS coronavirus replication. Emerg Infect Dis. 2004;10(2):317‐319.
    1. Paragas J, Blatt L, Hartmann C, Huggins J, Endy T. Interferon alfacon1 is an inhibitor of SARS‐corona virus in cell‐based models. Antiviral Res. 2005;66(2‐3):99‐102.
    1. Totura AL, Whitmore A, Agnihothram S, et al. Toll‐like receptor 3 signaling via TRIF contributes to a protective innate immune response to severe acute respiratory syndrome coronavirus infection. MBio. 2015;6(3):e00638‐15.
    1. Ziegler CGK, Allon SJ, Nyquist SK, et al. SARS‐CoV‐2 receptor ACE2 is an interferon‐stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell. 2020;181:1016–1035.
    1. Zhang C, Wu Z, Li J‐W, Zhao H, Wang GQ. The cytokine release syndrome (CRS) of severe COVID‐19 and Interleukin‐6 receptor (IL‐6R) antagonist Tocilizumab may be the key to reduce the mortality. Int J Antimicrob Agents. 2020;55:105954
    1. Conti P, Gallenga CE, Tetè G, et al. How to reduce the likelihood of coronavirus‐19 (CoV‐19 or SARS‐CoV‐2) infection and lung inflammation mediated by IL‐1. J Biol Regul Homeost Agents. 2020;34(2):11–16.
    1. Conti P, Ronconi G, Caraffa A, et al. Induction of pro‐inflammatory cytokines (IL‐1 and IL‐6) and lung inflammation by Coronavirus‐19 (COVI‐19 or SARS‐CoV‐2): anti‐inflammatory strategies. J Biol Regul Homeost Agents. 2020;34(2).
    1. Ledford H. Coronavirus breakthrough: dexamethasone is first drug shown to save lives. Nature. 2020;582:469
    1. Hoffmann M, Schroeder S, Kleine‐Weber H, Müller MA, Drosten C, Pöhlmann S. Nafamostat Mesylate Blocks Activation of SARS‐CoV‐2: New Treatment Option. The Currently Unfolding Coronavirus Pandemic Threatens Health Systems and Economies. 2020. . Accessed April 27, 2020.
    1. Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005;2(1):69.
    1. Keyaerts E, Vijgen L, Maes P, Neyts J, Van Ranst M. In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem Biophys Res Commun. 2004;323(1):264‐268.
    1. Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). Clin Infect Dis. 2020. [Online ahead of print].
    1. Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS‐CoV‐2 infection in vitro. Cell Discov. 2020;6(1):16.
    1. Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID‐19 associated pneumonia in clinical studies. Biosci Trends. 2020;14(1):72‐73.
    1. Gautret P, Lagier J‐C, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID‐19: results of an open‐label non‐randomized clinical trial. Int J Antimicrob Agents. 2020;105949.
    1. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA‐approved Drug Ivermectin inhibits the replication of SARS‐CoV‐2 in vitro. Antiviral Res. 2020;178:104787
    1. Kuster GM, Pfister O, Burkard T, et al. SARS‐CoV2: should inhibitors of the renin–angiotensin system be withdrawn in patients with COVID‐19? Eur Heart J. 2020;41:1801–1803.
    1. Meng J, Xiao G, Zhang J, et al. Renin‐angiotensin system inhibitors improve the clinical outcomes of COVID‐19 patients with hypertension. Emerg Microbes Infect. 2020;9(1):757‐760.
    1. Sukumaran V, Tsuchimochi H, Tatsumi E, Shirai M, Pearson JT. Azilsartan ameliorates diabetic cardiomyopathy in young db/db mice through the modulation of ACE‐2/ANG 1–7/Mas receptor cascade. Biochem Pharmacol. 2017;144:90‐99.
    1. Fosbøl EL, Butt JH, Østergaard L, et al. Association of angiotensin‐converting enzyme inhibitor or angiotensin receptor blocker use with COVID‐19 diagnosis and mortality. JAMA. 2020;126:1671–1681.
    1. Hoffmann M, Schroeder S, Kleine‐Weber H, Müller MA, Drosten C, Pöhlmann S. Nafamostat mesylate blocks activation of SARS‐CoV‐2: new treatment option for COVID‐19. Antimicrob Agents Chemother. 2020;64:754–820.
    1. Hoffmann M, Kleine‐Weber H, Schroeder S, et al. SARS‐CoV‐2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271–280.
    1. Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today's diseases. Lancet Infect Dis. 2003;3(11):722‐727.
    1. Pantoliano MW, Petrella EC, Kwasnoski JD, et al. High‐density miniaturized thermal shift assays as a general strategy for drug discovery. J Biomol Screen. 2001;6(6):429‐440.
    1. Tripathy S, Dassarma B, Roy S, Chabalala H, Matsabisa MG. A review on possible modes of action of chloroquine/hydroxychloroquine: repurposing against SAR‐CoV‐2 (COVID‐19) pandemic. Int J Antimicrob Agents. 2020;106028.
    1. Schrezenmeier E, Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020;16(3):155‐166.
    1. Statement on IJAA Paper. International Society of Antimicrobial Chemotherapy. . Accessed April 30, 2020.
    1. Gielen V, Johnston SL, Edwards MR. Azithromycin induces anti‐viral responses in bronchial epithelial cells. Eur Respir J. 2010;36(3):646‐654.
    1. Deretic V, Timmins GS. Azithromycin and ciprofloxacin have a chloroquine‐like effect on respiratory epithelial cells. bioRxiv. 2020. . Accessed April 5, 2020.
    1. Pani A, Lauriola M, Romandini A, Scaglione F. Macrolides and viral infections: focus on azithromycin in COVID‐19 pathology. Int J Antimicrob Agents. 2020;106053.
    1. Aghai ZH, Kode A, Saslow JG, et al. Azithromycin suppresses activation of nuclear factor‐kappa B and synthesis of pro‐inflammatory cytokines in tracheal aspirate cells from premature infants. Pediatr Res. 2007;62(4):483‐488.
    1. Taylor SP, Sellers E, Taylor BT. Azithromycin for the prevention of COPD exacerbations: the good, bad, and ugly. Am J Med. 2015;128(12):1362.
    1. Bouwman JJ, Visseren FL, Bouter PK, Diepersloot RJ. Azithromycin inhibits interleukin‐6 but not fibrinogen production in hepatocytes infected with cytomegalovirus and chlamydia pneumoniae. J Lab Clin Med. 2004;144(1):18‐26.
    1. Ulrich H, Pillat MM. CD147 as a target for COVID‐19 treatment: suggested effects of azithromycin and stem cell engagement. Stem Cell Rev Reports. 2020;16:434–440.
    1. Wagstaff KM, Sivakumaran H, Heaton SM, Harrich D, Jans DA. Ivermectin is a specific inhibitor of importin α/β‐mediated nuclear import able to inhibit replication of HIV‐1 and dengue virus. Biochem J. 2012;443(3):851‐856.
    1. Lundberg L, Pinkham C, Baer A, et al. Nuclear import and export inhibitors alter capsid protein distribution in mammalian cells and reduce Venezuelan Equine Encephalitis Virus replication. Antiviral Res. 2013;100(3):662‐672.
    1. Tay MYF, Fraser JE, Chan WKK, et al. Nuclear localization of dengue virus (DENV) 1–4 non‐structural protein 5; protection against all 4 DENV serotypes by the inhibitor Ivermectin. Antiviral Res. 2013;99(3):301‐306.
    1. Patel A. Usefulness of Ivermectin in COVID‐19 Illness. 2020. . Accessed April 27, 2020.
    1. Momekov G, Momekova D. Ivermectin as a potential COVID‐19 treatment from the pharmacokinetic point of view: antiviral levels are not likely attainable with known dosing regimens. Biotechnol Biotechnol Equip. 2020;34(1):469–474. 10.1101/2020.04.11.20061804.
    1. Gubareva LV, Kaiser L, Hayden FG. Influenza virus neuraminidase inhibitors. Lancet. 2000;355(9206):827‐835.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe